Trump signs executive order to accelerate psychedelic research and FDA approval for veterans
President Donald Trump signed an executive order on Saturday to accelerate research and FDA approval of psychedelic-based therapies, targeting treatments for post-traumatic stress disorder (PTSD), depression, addiction, and other mental health conditions, with a particular focus on helping veterans. The move aims to remove bureaucratic hurdles, expedite reviews for psychedelics designated as breakthrough therapies, and facilitate faster rescheduling of approved drugs, as Trump announced in the Oval Office.
Joining Trump for the signing were high-profile figures including Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, podcaster Joe Rogan, and military veterans. According to ABC News, Trump emphasized the order's goal to provide veterans with "new options for treatment," highlighting substances like ibogaine, which has been used outside the U.S. for PTSD. Bloomberg reported the directive specifically eases restrictions to speed up access to such therapies already in use abroad.
Trump described the psychedelics as "one of the hottest things" in medical research, noting their life-changing potential for severe mental illness. In remarks captured on video, he stated the order would improve data sharing between the FDA and the Department of Veterans Affairs, paving the way for quicker approvals. The Independent noted Rogan's presence as a special guest, despite his past criticisms of Trump, adding a layer of unexpected bipartisanship to the event.
This executive action matters deeply for millions affected by mental health crises, especially the roughly 20% of U.S. veterans battling PTSD, who often face limited treatment options amid the opioid epidemic. By prioritizing psychedelics—substances long restricted due to their Schedule I status under federal law—the order could usher in innovative therapies shown in early studies to outperform traditional antidepressants for some patients.
Looking ahead, the FDA must now implement expedited reviews, while HHS oversees expanded research and access. Agencies like the VA will collaborate on trials, potentially leading to breakthroughs within months if data supports it. As reported across sources, Trump predicted many psychedelics "will go very quickly" once hurdles are cleared, signaling a shift in U.S. drug policy toward embracing experimental mental health solutions.